Skip to main content

Market Overview

Return On Capital Employed Overview: Eli Lilly


Looking at Q4, Eli Lilly (NYSE:LLY) earned $1.99 billion, a 55.84% increase from the preceding quarter. Eli Lilly also posted a total of $7.44 billion in sales, a 29.59% increase since Q3. In Q3, Eli Lilly earned $1.28 billion, and total sales reached $5.74 billion.

What Is Return On Capital Employed?

Changes in earnings and sales indicate shifts in Eli Lilly's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q4, Eli Lilly posted an ROCE of 0.34%.

It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.

ROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Eli Lilly is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.

In Eli Lilly's case, the positive ROCE ratio will be something investors pay attention to before making long-term financial decisions.

Q4 Earnings Recap

Eli Lilly reported Q4 earnings per share at $2.75/share, which beat analyst predictions of $2.35/share.


Related Articles (LLY)

View Comments and Join the Discussion!

Posted-In: BZI-ROCEEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at